Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending October 18, 2016. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them. The filing details the re-investment of dividends into the Company's 2009 Performance Share Plan.
Key Financial Metrics
The filing does not provide corporate financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to specific share transactions:
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Price: All reported transactions occurred at a uniform price of £17.00 per share.
- Transaction Date: October 13, 2016.
- Transaction Nature: Increase in notional interest following dividend re-investment.
Material Changes
The filing does not report material changes to the company's financial position, operations, or strategy compared to prior periods. It strictly documents routine compliance notifications for share plan adjustments.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a regulatory disclosure of specific shareholding changes.
Important Facts for Investors
- Executive Participation: Multiple senior executives, including CEO Sir Andrew Witty and CEO Designate Ms. E. Walmsley, participated in the dividend re-investment plan.
- Transaction Volume: Aggregated volumes varied by executive, with Sir Andrew Witty acquiring 16,936.13 shares and Dr. P. J. T. Vallance acquiring 7,568.381 shares.
- Market Price Context: The transactions reflect a share price of £17.00 on October 13, 2016.
- No Corporate Financials: Investors should not use this document for financial performance analysis; refer to Form 20-F or quarterly reports for revenue and earnings data.